Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: a clinical narrative review
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Echeverría Esnal, Daniel
- dc.contributor.author Sorli Redó, M. Luisa
- dc.contributor.author Navarrete Rouco, Maria Eugenia
- dc.contributor.author Prim, Núria
- dc.contributor.author Barceló-Vidal, Jaime
- dc.contributor.author Conde Estévez, David
- dc.contributor.author Milagro Montero, Maria
- dc.contributor.author Martín-Ontiyuelo, Clara
- dc.contributor.author Horcajada Gallego, Juan Pablo
- dc.contributor.author Grau Cerrato, Santiago
- dc.date.accessioned 2024-05-15T06:20:14Z
- dc.date.issued 2023
- dc.description.abstract Introduction: Enterococcus faecium is a commensal microorganism that can cause infections such as bacteremia. Incidence of ampicillin-resistant and vancomycin-susceptible E. faecium (EfARSV) bacteremia is on the rise, and the mortality rate is high. Despite much data, the most appropriate treatment remains a question. Areas covered: This article mostly reviews the relevant aspects of EfARSV bacteremia: microbiology, gastrointestinal tract colonization and invasion, antibiotic resistance, epidemiology, risk factors, mortality, and treatment, including pharmacologic components of employed agents and related clinical evidence. A literature search was conducted on PubMed on 31 July 2022, which was updated on 15 November 2022. Expert opinion: EfARSV bacteremia presents high mortality. However, it is uncertain whether mortality is attributable to or a marker of severity/comorbidities. Considering its antibiotic resistance pattern, EfARSV is considered a difficult-to-treat microorganism. Glycopeptides have been used to treat EfARSV, with linezolid and daptomycin serving as potential alternative agents. Yet, the use of daptomycin is controversial due to a higher risk of treatment failures. Clinical evidence on this issue is scarce, unfortunately, and subject to many limitations. Despite increased incidence and mortality, EfARSV bacteremia presents multiple aspects to be addressed in well-conducted studies.
- dc.format.mimetype application/pdf
- dc.identifier.citation Echeverria-Esnal D, Sorli L, Navarrete-Rouco ME, Prim N, Barcelo-Vidal J, Conde-Estévez D, et al. Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: a clinical narrative review. Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):759-75. DOI: 10.1080/14787210.2023.2223977
- dc.identifier.doi http://dx.doi.org/10.1080/14787210.2023.2223977
- dc.identifier.issn 1478-7210
- dc.identifier.uri http://hdl.handle.net/10230/60151
- dc.language.iso eng
- dc.publisher Taylor & Francis
- dc.relation.ispartof Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):759-75
- dc.rights © This is an Accepted Manuscript of an article published by Taylor & Francis in Expert review of anti-infective therapy on 2023 Jul-Dec, available online: http://www.tandfonline.com/10.1080/14787210.2023.2223977.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Bacteremia
- dc.subject.keyword Enterococcus faecium
- dc.subject.keyword Bloodstream infection
- dc.subject.keyword Daptomycin
- dc.subject.keyword Linezolid
- dc.subject.keyword Oritavancin
- dc.subject.keyword Teicoplanin
- dc.subject.keyword Vancomycin
- dc.title Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: a clinical narrative review
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion